Lurbinectedin
Zepzelca, Lurbinectedin (lurbinectedin) is a small molecule pharmaceutical. Lurbinectedin was first approved as Zepzelca on 2020-06-15. It is used to treat small cell lung carcinoma in the USA. Zepzelca's patent is valid until 2024-12-13 (FDA).
Trade Name | Lurbinectedin |
---|---|
Common Name | Lurbinectedin |
Indication | small cell lung carcinoma |
Drug Class | Ecteinascodin derivatives |